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The ﬁrst issue of Nature Medicine published 20 years ago featured an article that reported Japan's critical
situation regarding clinical trials, calling for major reform. Twenty years later, Japan has enacted three
laws to promote the use of regenerative medicine as a national policy. The ﬁrst law to be enacted was the
Regenerative Medicine Promotion Act, which represents the country's determination to work toward the
promotion of regenerative medicine. Subsequently, the Pharmaceuticals, Medical Devices, and Other
Therapeutic Products Act (PMD Act) and the Act on the Safety of Regenerative Medicine (RM Act) came
into effect. The PMD Act created a new category for regenerative medicine products, and established the
process for obtaining approval for cell therapy and other regenerative therapies through the imple-
mentation of clinical trials. The RM Act speciﬁed the regulations that doctors, review committees, and
cell culture/processing facilities must adhere to when providing regenerative medicine in medical care,
not only in clinical research but also in private practice.
Previously, researchers in regenerative medicine only had a set of guidelines to follow for conducting
clinical research. Now, with the enactment of the RM Act, all areas for improvement that had been
enumerated 20 years agodsuch as the lack of appropriate review committees and governmental con-
troldhave been addressed by law, creating a system that gives the highest priority to patient safety. In
this paper, we present the particularly noteworthy points of the RM Act, along with the actual current
conditions of regenerative medicine in Japanese medical care.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Perspective
In the ﬁrst issue of Nature Medicine published in 1995,
Fukushima [1] emphasized inadequacy in the implementation of
clinical trials in Japan. In the report, the author pointed out the lack
of infrastructure for informed consent, as well as institutional re-
view board (IRB), and governmental control, indicating the need for
an overhaul of the entire ﬁeld of translational medicine in Japan. Inenerative Medicine, Research
inistry of Health, Labour and
igaseki, Chiyoda-ku, Tokyo
03 0595.
obita).
se Society for Regenerative
ative Medicine. Production and ho2014, approximately 20 years after this initial report, Japan enacted
the Regenerative Medicine Promotion Act, followed by two other
associated Acts concerning translational regenerative medicine
[2,3] (Fig. 1). The ﬁrst is the Pharmaceuticals, Medical Devices, and
Other Therapeutic Products Act (PMD Act, renamed from the
Revised Pharmaceutical Affairs Act), which newly created a cate-
gory for regenerative medical products in addition to the existing
categories pharmaceutical products, medical device products,
quasi-drugs and cosmetics. Furthermore, by adopting a systemwith
conditional and time-limited approval for regenerative medicine
products, the PMD Act established the process for obtaining
approval for cell therapy and other regenerative therapies through
the implementation of clinical trials [4]. The PMD Act regulates the
production and marketing of regenerative and cellular therapeutic
products by ﬁrms.sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. Japan has enacted three laws to promote the use of regenerative medicine as a national policy. The ﬁrst law to be enacted was the Regenerative Medicine Promotion Act,
which represents the country's determination to work toward the promotion of regenerative medicine, following which the Pharmaceuticals, Medical Devices, and Other Ther-
apeutic Products Act (PMD Act) and the Act on the Safety of Regenerative Medicine (RM Act) came into effect.
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(RM Act), which established a framework for regenerative medicine
provided both in clinical research (not including clinical trials
complyingwith international guidelines, including the InternationalFig. 2. Risk Classiﬁcation of Class I, Class II, and Class III Regenerative Medical Technolog
transferred cells), hematopoietic stem cell transplantation (excluding those that use gen
embryotic stem cells established from human sperm or unfertilized eggs) are excluded byCouncil for Harmonization of Technical Requirements for Pharma-
ceuticals for Human Use [ICH]-Good Clinical Practice [GCP]) and
private practice (not covered by health insurance) and clariﬁed the
measures necessary for ensuring patient safety. Under the Medicaly. *: Medical technologies such as blood transfusion (excluding those that use gene-
e-transferred cells), and assisted reproductive technology (excluding those that use
the cabinet order.
Table 1
Current implementation status of regenerative medicine research and therapies under the RM Acta (the end of November 2015).
Number of the regenerative medicine provision plans
Type of classes Number of
provision plans
(Total)
Number of provision
plans (Clinical
research and private
practice)
Others (The target diseases or type of regenerative medical technologies)
Class I 11 Clinical research: 9 The processed cells of regenerative medical technologies are mainly shown as
follows.
- Adipose-derived cells (allogeneic) (severe familial hypercholesterolemia)
- Corneal endothelial cells (bullous keratopathy)
- Hematopoietic stem cell (ex-vivo gene therapy) (chronic granulomatous
disease)
- Immune-competent cells (allogeneic) (biological response modiﬁer after liver
transplantation, infection treatment after hematopoietic stem cell
transplantation)
- Immune-competent cells (ex-vivo gene therapy) (acute myeloid leukemia)
- Islet cells (diabetes)
- Liver cells (allogeneic) (hyperammonemia)
Private practice: 2 Under deliberation in the Health Science Council.b
Class II 48 Clinical research: 24 The processed cells of regenerative medical technologies are mainly shown as
follows.
- Adipose-derived cells (breast reconstruction, cartilage injuries, stress urinary
incontinence, ischemic heart disease, buerger's disease, periodontal disease)
- Bone marrow-derived cells (buerger's disease, nonunion, mandibular defect,
spinal cord injury, articular cartilage lesion)
- Cartilage cells (meniscal lesions of the knee)
- Cord blood derived cells (hypoxic ischemic encephalopathy)
- Dental pulp-derived cells (atrophy of alveolar bone)
- Mucosal epithelial cells (intractable keratoconjunctival disease)
- Myoblast (severe cardiomyopathy)
- Periosteal cells (periodontal disease)
- Peripheral blood mononuclear cells (non-healing wound)
Etc
Private practice: 24 The processed cells of regenerative medical technologies are mainly shown as
follows.
- Adipose-derived cells (cosmetic treatment, atopic dermatitis).
- Bone marrow-derived cells (buerger's disease)
- Epithelial cells (cosmetic treatment)
- Fibroblasts (cosmetic treatment)
- Hair follicle cells (alopecia)
- Peripheral blood cells (peripheral vascular disease)
- Platelet-rich plasma (meniscal lesions of the knee, arthritis)
Etc
Class III 1831 Clinical research: 37 The processed cells of regenerative medical technologies are mainly shown as
follows.
- Adipose-derived cells (non-culture) (breast reconstruction)
- Immune-competent cells (malignant tumor)
- Platelet-rich plasma (intractable skin ulcers, atrophy of alveolar bone,
peripheral arterial disease)
Etc.
Private practice: 1794 The processed cells of regenerative medical technologies are mainly shown as
follows.
- Adipose-derived cells (non-culture) (cosmetic treatment)
- Immune-competent cells (malignant tumor)
- Platelet-rich plasma (cosmetic treatment, atrophy of alveolar bone)
Etc
a The act on safety of regenerative medicine.
b In class I regenerative medicine, a certain period of restricted implementation period will be imposed, and the Ministry of Health, Labour and Welfare will conﬁrm the
safety, etc., by hearing opinions of the Health Science Council within the period.
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regenerativemedical technologies using processed cells for ensuring
the safety and adequacy.
Regenerative medical technologies and Regenerative medical
products are deﬁned as processed live human/animal cells that are
intended to be used for either (1) the reconstruction, repair, or
formation of structures or functions of the human body, or (2) the
treatment or prevention of human diseases. Regenerative medical
products also include gene therapy products.
November 2015 marked the end of the one-year period of
transitional measures for the RM Act, and we are now able to
witness the actual conditions of the clinical research activities and
therapies in regenerative medicine currently conducted in Japanunder this Act. In this paper, we provide an overview of how
translational regenerative medicine in Japan has changed in the
past 20 years, along with the actual conditions of regenerative
medicine provided under the RM Act.
Previously, researchers in regenerative medicine had only one
major guideline to follow (“Guidelines on Clinical Research Using
Human Stem Cells”) when conducting clinical research. Starting in
November 2014, researchers have been required to complywith the
RM Act in the provision of regenerative medicine. Furthermore, the
RM Act applies not only to clinical research but also to private
practice. The intention behind this Act is to have a clear grasp of the
actual conditions of regenerative medicine used as therapies to
ensure patient safety. In this paper, we present some of the
M. Tobita et al. / Regenerative Therapy 4 (2016) 78e81 81regulatory requirements speciﬁed in the RM Act. Regarding
informed consent, which was one of the aspects that Fukushima [1]
strongly pointed out as in need of reform, the RM Act presents the
requirements for not only recipients of regenerative therapies but
also for the donors. Furthermore, the Act includes requirements for
the protection of vulnerable populations involved in research and
appropriate compensation/treatment for subjects who may be
harmed as a result of participating in research, both of which were
included in the revised Declaration of Helsinki in 2013 [5].
Another area for improvement identiﬁed by Fukushima
involved the empowerment of IRBs. In the RM Act, regenerative
medical techniques are classiﬁed into high risk (Class I), interme-
diate risk (Class II), and low risk (Class III) (Fig. 2). To review these
classiﬁed techniques properly, the Act speciﬁes the requirements
for two types of certiﬁed committees: certiﬁed committees for
regenerative medicine to review Class III techniques, and certiﬁed
special committees for regenerative medicine to review Class I and
II techniques. The latter committee requires higher review capa-
bilities and objectivity.
These certiﬁed committees for regenerative medicine can be
formed by universities, academic societies of medical science, and
general incorporated associations; moreover, there must be no
conﬂict of interest within the committee. Certiﬁed committees for
regenerative medicine are authorized to issue opinions regarding
the provision of regenerative medicine in both clinical research and
private practice, adverse event reports, and annual reports. Addi-
tionally, information on reviews conducted by the committees is to
be shared with the public.
Another notable characteristic of the RM Act is that, when
providing regenerativemedicine in research or private practice, it is
now possible to outsource the cell culture/processing to private
contractors. The use of companies that specialize in cell cultivation
can secure the safety of cell culture and ensures a steady supply of
cells. This allows doctors to focus speciﬁcally on treatment and
research, potentially further promoting the use of regenerative
medicine.
Regarding the current implementation status of regenerative
medicine research and therapies under the RM Act as of the end of
November 2015, the numbers of regenerative medicine provision
plans submitted are 11 for Class I (9 research studies and 2 private
practice applications), 48 for Class II (24 research and 24 private
practice), and 1831 for Class III (37 research and 1794 private
practice). There are 26 certiﬁed special committees to review Class I
and Class II regenerative medicine provision plans, and there are 88
certiﬁed committees to review Class III regenerative medicine
provision plans. With respect to the operating status of cell culture/
processing facilities, there are 2194 facilities established within
medical institutions and 41 facilities that are outside hospitals or
are run by corporations. Currently, no overseas facilities manufac-
ture the processed cells for use in Japan (Table 1). Since the RM Act
also applies to the use of platelet-rich plasma (PRP), operatingrooms that perform minimal manipulations such as collection of
PRP are also required to ﬁle an application to be registered as cell
culture/processing facilities. These operating rooms are included in
the number of cell culture/processing facilities within medical
institutions.
We have presented the current status of clinical research and
private practice in regenerative medicine in Japan after the one-
year transitional period has ended. Regarding the lack of govern-
mental control, which Fukushima regarded as the most pressing
issue in 1995, Japan has now adopted a new system to protect
patients' lives, in which the government is authorized to issue re-
quests for reports, improvement orders, and emergency interim
orders to regenerative medicine institutes, certiﬁed committees for
regenerative medicine, and cell culture/processing facilities.
Although the RM Act was ﬁnally enacted after 20 years of antici-
pation among many researchers and patients, many issues still
need to be resolved for the promotion of regenerative medicine.
Considerations are underway on how to best evaluate the safety of
cell transplantation using induced pluripotent stem cells and other
cells, and the establishment of support systems to implement high-
quality clinical research. There is also a plan to help citizens un-
derstand the regenerative medicine currently applied in both
research and therapeutic contexts, by disclosing the implementa-
tion status to the public. Moreover, Japan has been preparing laws
concerning the implementation of other translational research
activities outside of regenerative medicine, thereby promoting the
reform of translational medicine as a whole.
As a law that regulates clinical research and therapies in
regenerative medicine, the RM Act is globally unprecedented.
Although it will take some time before we can determine its effects
on the promotion of regenerative medicine, at this point, we can at
least say that many Japanese people support the law. Finally, we
would like to express our deep appreciation to everyone involved in
the efforts to enact the RM Act. We sincerely hope that many Jap-
anese people will beneﬁt from regenerative medicine.Competing ﬁnancial interests
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